Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KOD logo KOD
Upturn stock ratingUpturn stock rating
KOD logo

Kodiak Sciences Inc (KOD)

Upturn stock ratingUpturn stock rating
$8.97
Last Close (24-hour delay)
Profit since last BUY99.78%
upturn advisory
Regular Buy
BUY since 83 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: KOD (4-star) is a STRONG-BUY. BUY since 83 days. Profits (99.78%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.25

1 Year Target Price $7.25

Analysts Price Target For last 52 week
$7.25 Target price
52w Low $1.92
Current$8.97
52w High $11.6

Analysis of Past Performance

Type Stock
Historic Profit 605.85%
Avg. Invested days 49
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 493.35M USD
Price to earnings Ratio -
1Y Target Price 7.25
Price to earnings Ratio -
1Y Target Price 7.25
Volume (30-day avg) 6
Beta 2.42
52 Weeks Range 1.92 - 11.60
Updated Date 08/28/2025
52 Weeks Range 1.92 - 11.60
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.64

Earnings Date

Report Date 2025-08-12
When Before Market
Estimate -1.04
Actual -1.03

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.38%
Return on Equity (TTM) -140.33%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 434857550
Price to Sales(TTM) -
Enterprise Value 434857550
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.12
Shares Outstanding 52821700
Shares Floating 29509383
Shares Outstanding 52821700
Shares Floating 29509383
Percent Insiders 5.52
Percent Institutions 79.24

ai summary icon Upturn AI SWOT

Kodiak Sciences Inc

stock logo

Company Overview

overview logo History and Background

Kodiak Sciences Inc. is a biopharmaceutical company founded in 2006. It focuses on developing novel therapies to treat chronic, high-prevalence retinal diseases. Initially, the company focused on its Antibody Biopolymer Conjugate (ABC) platform, designed to extend the durability and improve the delivery of ophthalmic therapies.

business area logo Core Business Areas

  • Ophthalmology: Focuses on developing treatments for retinal diseases, primarily using its ABC Platform. This platform is the foundation for their lead product candidate, tarcocimab tedromer (KSI-301).

leadership logo Leadership and Structure

Kodiak Sciences is led by Victor Perlroth, MD, as CEO. The company's structure includes research and development, clinical operations, and administrative functions, typical of a biotechnology firm.

Top Products and Market Share

overview logo Key Offerings

  • Tarcocimab Tedromer (KSI-301): KSI-301 is Kodiak's lead product candidate, an anti-VEGF therapy utilizing the ABC platform designed for extended durability in treating wet AMD, DME, and RVO. As a pre-commercial product, it currently holds no market share. Key competitors include Eylea (Regeneron), Lucentis and Vabysmo (Roche/Genentech), and Beovu (Novartis).

Market Dynamics

industry overview logo Industry Overview

The ophthalmology market, particularly for retinal diseases, is substantial and growing due to an aging population and increasing prevalence of diabetes. The market is competitive with established players and biosimilar threats.

Positioning

Kodiak Sciences aims to differentiate itself with KSI-301 by offering longer treatment intervals compared to existing anti-VEGF therapies, potentially reducing the burden of frequent injections for patients. Their success depends on clinical trial outcomes and regulatory approvals.

Total Addressable Market (TAM)

The global market for retinal disease therapies is estimated to be in the tens of billions of dollars annually. Kodiak is attempting to capture a significant portion of this by addressing the unmet need for longer-lasting treatments. If approved the TAM could be $12 billion by 2028

Upturn SWOT Analysis

Strengths

  • Proprietary ABC platform with potential for extended durability
  • Targeting large and growing ophthalmology market
  • Experienced management team

Weaknesses

  • Single lead product candidate (KSI-301) creates high dependence
  • Clinical trial failures and delays
  • High cash burn rate
  • Limited revenue stream

Opportunities

  • Positive clinical trial data could lead to rapid market adoption
  • Potential for partnerships or acquisitions by larger pharmaceutical companies
  • Expansion of ABC platform to other therapeutic areas

Threats

  • Clinical trial failures or regulatory disapproval
  • Competition from established anti-VEGF therapies and biosimilars
  • Changing reimbursement landscape
  • Possible fund raising efforts which could delute shareholders.

Competitors and Market Share

competitor logo Key Competitors

  • REGN
  • RHHBY
  • NVS

Competitive Landscape

Kodiak faces intense competition from established players with approved anti-VEGF therapies. Its advantage lies in potentially longer treatment intervals if KSI-301 is successful.

Growth Trajectory and Initiatives

Historical Growth: Historically, growth has been driven by the advancement of KSI-301 through clinical trials.

Future Projections: Future growth hinges on successful clinical trial outcomes, regulatory approval, and commercial launch of KSI-301. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing KSI-301 through Phase 3 clinical trials and exploring potential partnerships.

Summary

Kodiak Sciences is a high-risk, high-reward biopharmaceutical company dependent on the success of its lead product candidate, KSI-301. The company's strengths lie in its innovative ABC platform and focus on a large market. Its weaknesses include reliance on a single product, while they must be aware of well-established competitors. Success depends on positive clinical trial data and navigating the complex regulatory landscape.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Industry Publications
  • Kodiak Sciences Website

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kodiak Sciences Inc

Exchange NASDAQ
Headquaters Palo Alto, CA, United States
IPO Launch date 2018-10-04
Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 121
Full time employees 121

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.